COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
Saved in:
| Title: | COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics. |
|---|---|
| Authors: | Agarwal R; Division of Nephrology, Department of Medicine, Richard L. Roudebush VA Medical Center & Indiana University School of Medicine, Indianapolis, IN, USA., Green JB; Division of Endocrinology, Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA., Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands., Mann JFE; KfH Kidney Centre, Munich, Germany.; Department of Nephrology & Hypertension, Friedrich Alexander University, Erlangen, Germany., McGill JB; Division of Endocrinology, Metabolism & Lipid Research, Washington University School of Medicine in St. Louis, St Louis, MO, USA., Mottl AK; University of North Carolina Kidney Center, UNC School of Medicine, Chapel Hill, NC, USA., Rosenstock J; Velocity Clinical Research at Medical City, Dallas, TX, USA.; University of Texas Southwestern Medical Center, TX, USA., Rossing P; Steno Diabetes Center Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Vaduganathan M; Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Brinker M; Cardiology and Nephrology Clinical Development, Bayer AG, Wuppertal, Germany., Edfors R; Department of Clinical Sciences, Danderyd University Hospital, Division of Cardiovascular Medicine, Karolinska Institutet, Stockholm, Sweden., Li N; Bayer Healthcare, Chaoyang District, Beijing, China., Scheerer MF; Global Medical Affairs and Pharmacovigilance, Bayer AG, Berlin, Germany., Scott C; Clinical Statistics and Analytics, Bayer PLC, Reading, UK., Nangaku M; Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan. |
| Corporate Authors: | CONFIDENCE investigators |
| Source: | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2025 Aug 01; Vol. 40 (8), pp. 1559-1569. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 8706402 Publication Model: Print Cited Medium: Internet ISSN: 1460-2385 (Electronic) Linking ISSN: 09310509 NLM ISO Abbreviation: Nephrol Dial Transplant Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
